Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis

Abstract

Background: Within multiple sclerosis lesions, brain-derived neurotrophic factor is detected in neurons and immunocytes.

Objective: To clarify brain-derived neurotrophic factor production by peripheral blood immunocytes and its relationship with clinical parameters in multiple sclerosis.

Methods: Serum brain-derived neurotrophic factor levels were measured by conventional enzyme-linked immunosorbent assay while brain-derived neurotrophic factor production by immunocytes was determined by an in situ enzyme-linked immunosorbent assay in 74 multiple sclerosis patients, 32 healthy controls, and 86 patients with other neurological diseases. The tyrosine kinase receptor TrkB expression level in peripheral blood mononuclear cells was measured by real-time polymerase chain reaction.

Results: Multiple sclerosis patients showed significantly higher serum brain-derived neurotrophic factor levels than healthy controls and patients with other neurological diseases. Multiple sclerosis patients with high brain-derived neurotrophic factor levels were younger, and showed fewer relapse numbers than those with low brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production by T cells increased with age in healthy controls, but not in multiple sclerosis patients. Interferon beta induced a significant increase in serum brain-derived neurotrophic factor levels. Brain-derived neurotrophic factor production from T cells and TrkB expression levels in peripheral blood mononuclear cells were significantly enhanced in interferon beta-treated multiple sclerosis patients compared with untreated ones. Conclusions: A high brain-derived neurotrophic factor level is related to early mild disease in young multiple sclerosis patients. Interferon beta potentiates brain-derived neurotrophic factor production and brain-derived neurotrophic factor receptor expression in peripheral blood mononuclear cells, which may act beneficially.

Keywords

Brain-derived neurotrophic factor BDNF multiple sclerosis MS interferon beta IFNβ T cells age

Get full access to this article

View all access options for this article.

References

Compston A. and Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.

Lewin GR and Barde YA Physiology of the neurotrophins. Annu Rev Neurosci 1996; 19: 289-317.

Gravel C. , Gotz R. , Lorrain A. and Sendtner M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons . Nat Med 1997; 3: 765-770.

McTigue DM , Horner PJ , Stokes BT and Gage FH Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci 1998; 18: 5354-5365.

Kerschensteiner M. , Gallmeier E. , Behrens L. , et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189: 865-870.

Stadelmann C. , Kerschensteiner M. , Misgeld T. , Bruck W. , Hohlfeld R. and Lassmann H.

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

Brain 2002; 125: 75-85.

Kerschensteiner M. , Stadelmann C. , Dechant G. , Wekerle H. and Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003; 53: 292-304.

Rosenfeld RD , Zeni L. , Haniu M. , et al. Purification and identification of brain-derived neurotrophic factor from human serum. Protein Expr Purif 1995; 6: 465-471.

Radka SF , Holst PA , Fritsche M. and Altar CA Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res 1996; 709: 122-301.

10.

Fujimura H. , Altar CA , Chen R. , et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost 2002; 87: 728-734.

11.

Nassenstein C. , Braun A. , Erpenbeck VJ , et al. The neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 are survival and activation factors for eosinophils in patients with allergic bronchial asthma. J Exp Med 2003; 198: 455-467.

12.

Nakahashi T. , Fujimura H. , Altar CA , et al. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett 2000; 470: 113-117.

13.

Donovan MJ , Miranda RC , Kraemer R. , et al. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol 1995; 147: 309-324.

14.

Leeksma CH and Cohen JA Determination of the life of human blood platelets using labelled diisopropylfluorophosphanate . Nature 1955; 175: 552-553.

15.

Poduslo JF and Curran GL Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Brain Res Mol Brain Res 1996; 36: 280-286.

16.

Pan W. , Banks WA , Fasold MB , Bluth J. and Kastin AJ Transport of brain-derived neurotrophic factor across the blood-brain barrier . Neuropharmacology 1998; 37: 1553-1561.

17.

Karege F. , Schwald M. and Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002; 328: 261-264.

18.

Lalive PH , Kantengwa S. , Benkhoucha M. , Juillard C. and Chofflon M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol 2008; 197: 147-151.

19.

Azoulay D. , Vachapova V. , Shihman B. , Miler A. and Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005; 167: 215-218.

20.

Sarchielli P. , Greco L. , Stipa A. , Floridi A. and Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 2002 ; 132: 180-188.

21.

Caggiula M. , Batocchi AP , Frisullo G. , et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 2005; 62: 176-182.

22.

Weinstock-Guttman B. , Zivadinov R. , Tamano-Blanco M. , et al. Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol 2007; 188: 167-174.

23.

Hamamcioglu K. and Reder AT Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 2007; 13: 459-470.

24.

Azoulay D. , Urshansky N. and Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol 2008; 195: 186-193.

25.

Sarchielli P. , Zaffaroni M. , Floridi A. , et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins . Mult Scler 2007; 13: 313-331.

26.

Blanco Y. , Moral EA , Costa M. , et al. Effect of glatiramer acetate (Copaxone) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett 2006; 406: 270-275.

27.

Petereit HF , Lindemann H. and Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler 2003; 9: 16-20.

28.

Polman CH , Reingold SC , Edan G. , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘‘McDonald Criteria’’. Ann Neurol 2005; 58: 840-846.

29.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.

30.

Kira J. , Kanai T. , Nishimura Y. , et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996; 40: 569-574.

31.

Matsuoka T. , Matsushita T. , Kawano Y. , et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007; 130: 1206-1223.

32.

Matsushita T. , Isobe N. , Matsuoka T. , et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibody-negative opticospinal multiple sclerosis in Japanese . Mult Scler 2009; 15: 834-847.

33.

Wingerchuk DM , Lennon VA , Pittock SJ , Lucchinetti CF and Weinshenker BG Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.

34.

Pozzilli C. , Prosperini L. , Sbardella E. , De Giglio L. , Onesti E. and Tomassini V. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci 2005; 26: S174-S178.

35.

Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2: 117-127.

36.

Ishizu T. , Kira J. , Osoegawa M. , et al. Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey. J Neurol Sci 2009; 280: 22-28.

37.

Edling AE , Nanavati T. , Johnson JM and Tuohy VK Human and murine lymphocyte neurotrophin expression is confined to B cells . J Neurosci Res 2004; 77: 709-717.

38.

Yamamoto H. and Gurney ME Human platelets contain brain-derived neurotrophic factor. J Neurosci 1990; 10: 3469-3478.

39.

Karege F. , Perret G. , Bondolfi G. , Schwald M. , Bertschy G. and Aubry JM Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109: 143-148.

40.

Shimizu E. , Hashimoto K. , Okamura N. , et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70-75.

41.

Karege F. , Bondolfi G. , Gervasoni N. , Schwald M. , Aubry JM and Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57: 1068-1072.

42.

Piccinni A. , Marazziti D. , Catena M. , et al. Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments . J Affect Disord 2008; 105: 279-283.

43.

Linker R. , Lee D-H. , Siglienti I. and Gold R.

Is there a role for neurotrophins in the pathology of multiple sclerosis?

J Neurol 2007; 254(Suppl): 133-140.

44.

Besser M. and Wank R. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1999 ; 162: 6303-6306.

45.

De Santi L. , Cantalupo L. , Tassi M. , Raspadori D. , Cioni C. and Annunziata P. Higher expression of BDNF receptor gp145trkB is associated with lower apoptosis intensity in T cell lines in multiple sclerosis . J Neurol Sci 2009; 277: 65-70.

46.

Schenone A. , Gill JS , Zacharias DA and Windebank AJ Expression of high- and low-affinity neurotrophin receptors on human transformed B lymphocytes. J Neuroimmunol 1996; 64: 141-149.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

0.09 MB

0.04 MB

0.02 MB

0.03 MB

0.06 MB

0.02 MB